Andres Henao Martinez
Concepts (533)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chagas Disease | 13 | 2023 | 41 | 6.650 |
Why?
| | Chagas Cardiomyopathy | 7 | 2023 | 27 | 4.020 |
Why?
| | Meningitis, Cryptococcal | 8 | 2024 | 34 | 3.360 |
Why?
| | Opportunistic Infections | 5 | 2026 | 47 | 3.320 |
Why?
| | Cryptococcosis | 6 | 2023 | 31 | 3.130 |
Why?
| | Antifungal Agents | 12 | 2026 | 153 | 3.030 |
Why?
| | Glucocorticoids | 5 | 2026 | 536 | 2.260 |
Why?
| | Trypanosoma cruzi | 6 | 2023 | 38 | 2.210 |
Why?
| | Transplant Recipients | 3 | 2026 | 177 | 2.030 |
Why?
| | Mycoses | 3 | 2026 | 87 | 1.890 |
Why?
| | Pneumonia, Pneumocystis | 2 | 2025 | 34 | 1.720 |
Why?
| | Cryptococcus neoformans | 4 | 2024 | 21 | 1.720 |
Why?
| | Zoonoses | 3 | 2026 | 39 | 1.670 |
Why?
| | Immunocompromised Host | 8 | 2026 | 201 | 1.650 |
Why?
| | Invasive Pulmonary Aspergillosis | 2 | 2023 | 7 | 1.570 |
Why?
| | Organ Transplantation | 3 | 2026 | 244 | 1.520 |
Why?
| | Candidemia | 4 | 2026 | 16 | 1.520 |
Why?
| | HIV Infections | 11 | 2026 | 3215 | 1.480 |
Why?
| | Travel | 6 | 2021 | 134 | 1.460 |
Why?
| | Fluconazole | 5 | 2026 | 24 | 1.440 |
Why?
| | Strongyloidiasis | 2 | 2024 | 4 | 1.310 |
Why?
| | Cryptococcus | 2 | 2024 | 16 | 1.290 |
Why?
| | Anti-Bacterial Agents | 11 | 2026 | 1942 | 1.250 |
Why?
| | Humans | 122 | 2026 | 146342 | 1.250 |
Why?
| | Adult | 50 | 2026 | 41087 | 1.200 |
Why?
| | Candida | 4 | 2026 | 46 | 1.190 |
Why?
| | Stroke, Lacunar | 2 | 2019 | 4 | 1.160 |
Why?
| | Hospitalization | 8 | 2026 | 2475 | 1.070 |
Why?
| | Transients and Migrants | 3 | 2023 | 28 | 1.070 |
Why?
| | Tuberculosis | 2 | 2022 | 290 | 1.050 |
Why?
| | Middle Aged | 37 | 2026 | 36619 | 1.020 |
Why?
| | Male | 59 | 2026 | 73396 | 1.010 |
Why?
| | Cardiomyopathies | 2 | 2021 | 340 | 1.000 |
Why?
| | Risk Factors | 19 | 2026 | 10921 | 1.000 |
Why?
| | Yellow Fever | 3 | 2022 | 9 | 0.990 |
Why?
| | Echinococcosis, Hepatic | 1 | 2026 | 2 | 0.940 |
Why?
| | Sporotrichosis | 1 | 2026 | 6 | 0.940 |
Why?
| | Echinococcosis | 1 | 2026 | 9 | 0.930 |
Why?
| | Bacteremia | 5 | 2023 | 218 | 0.930 |
Why?
| | Pneumocystis carinii | 1 | 2025 | 12 | 0.920 |
Why?
| | Coccidioidomycosis | 1 | 2025 | 8 | 0.920 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2019 | 188 | 0.910 |
Why?
| | Rubella | 1 | 2025 | 23 | 0.900 |
Why?
| | Mumps | 1 | 2025 | 21 | 0.900 |
Why?
| | Measles | 1 | 2025 | 48 | 0.870 |
Why?
| | Cytomegalovirus | 1 | 2026 | 172 | 0.870 |
Why?
| | Central Nervous System Neoplasms | 2 | 2018 | 177 | 0.860 |
Why?
| | Macrolides | 1 | 2025 | 68 | 0.850 |
Why?
| | Parasitemia | 2 | 2015 | 15 | 0.830 |
Why?
| | United States | 24 | 2026 | 16136 | 0.830 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 140 | 0.830 |
Why?
| | Pneumocystis | 1 | 2024 | 8 | 0.830 |
Why?
| | DNA, Viral | 1 | 2026 | 354 | 0.810 |
Why?
| | Cytomegalovirus Infections | 1 | 2026 | 206 | 0.810 |
Why?
| | Aged | 23 | 2026 | 26432 | 0.800 |
Why?
| | Immunosuppressive Agents | 2 | 2025 | 829 | 0.800 |
Why?
| | Female | 49 | 2026 | 79499 | 0.800 |
Why?
| | Pulmonary Aspergillosis | 1 | 2023 | 4 | 0.800 |
Why?
| | Nitroimidazoles | 1 | 2023 | 16 | 0.790 |
Why?
| | Drug Hypersensitivity | 1 | 2025 | 93 | 0.790 |
Why?
| | Myocarditis | 2 | 2016 | 103 | 0.770 |
Why?
| | Incidence | 6 | 2026 | 2936 | 0.770 |
Why?
| | Anemia, Aplastic | 1 | 2023 | 42 | 0.760 |
Why?
| | Retrospective Studies | 19 | 2026 | 17438 | 0.760 |
Why?
| | Pneumonia, Viral | 7 | 2020 | 387 | 0.760 |
Why?
| | Coronavirus Infections | 7 | 2020 | 379 | 0.760 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2024 | 130 | 0.750 |
Why?
| | Enterobacteriaceae Infections | 2 | 2013 | 43 | 0.740 |
Why?
| | Virus Diseases | 1 | 2024 | 219 | 0.710 |
Why?
| | Osteomyelitis | 2 | 2025 | 148 | 0.680 |
Why?
| | Antigens, Fungal | 2 | 2024 | 28 | 0.680 |
Why?
| | Neglected Diseases | 1 | 2020 | 5 | 0.660 |
Why?
| | Mycobacterium Infections | 2 | 2018 | 55 | 0.660 |
Why?
| | Hepatitis | 1 | 2020 | 43 | 0.640 |
Why?
| | Immunotherapy, Adoptive | 1 | 2024 | 356 | 0.640 |
Why?
| | Hantavirus Pulmonary Syndrome | 1 | 2020 | 5 | 0.620 |
Why?
| | Heart Aneurysm | 1 | 2019 | 11 | 0.610 |
Why?
| | Massive Hepatic Necrosis | 1 | 2019 | 3 | 0.590 |
Why?
| | Epidemics | 1 | 2020 | 97 | 0.590 |
Why?
| | Aneurysm, False | 1 | 2019 | 46 | 0.590 |
Why?
| | Hepatitis A | 1 | 2019 | 25 | 0.580 |
Why?
| | Neisseria gonorrhoeae | 1 | 2019 | 29 | 0.570 |
Why?
| | Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 3 | 0.570 |
Why?
| | Sarcoma, Myeloid | 1 | 2018 | 6 | 0.570 |
Why?
| | Hematoma, Subdural | 1 | 2018 | 20 | 0.570 |
Why?
| | Skin | 3 | 2022 | 701 | 0.540 |
Why?
| | Plasmodium falciparum | 1 | 2018 | 37 | 0.540 |
Why?
| | Malaria, Falciparum | 1 | 2018 | 32 | 0.540 |
Why?
| | Gonorrhea | 1 | 2019 | 63 | 0.530 |
Why?
| | Chromoblastomycosis | 1 | 2017 | 1 | 0.530 |
Why?
| | Population Groups | 1 | 2018 | 55 | 0.530 |
Why?
| | Hand Dermatoses | 1 | 2017 | 7 | 0.530 |
Why?
| | Fever | 2 | 2020 | 322 | 0.530 |
Why?
| | Renal Insufficiency | 1 | 2020 | 173 | 0.520 |
Why?
| | Dyspnea | 1 | 2019 | 251 | 0.520 |
Why?
| | Meningioma | 1 | 2018 | 87 | 0.520 |
Why?
| | Meningeal Neoplasms | 1 | 2018 | 95 | 0.520 |
Why?
| | Delayed Diagnosis | 1 | 2018 | 102 | 0.520 |
Why?
| | Medically Uninsured | 1 | 2018 | 134 | 0.510 |
Why?
| | Abscess | 1 | 2018 | 77 | 0.510 |
Why?
| | Milk | 1 | 2018 | 117 | 0.510 |
Why?
| | Latin America | 6 | 2022 | 96 | 0.490 |
Why?
| | Heart Failure | 2 | 2022 | 2329 | 0.490 |
Why?
| | Poliomyelitis | 3 | 2022 | 35 | 0.490 |
Why?
| | Pandemics | 10 | 2023 | 1707 | 0.490 |
Why?
| | Trichuriasis | 1 | 2016 | 4 | 0.480 |
Why?
| | Prisons | 4 | 2021 | 88 | 0.480 |
Why?
| | Pregnancy Complications, Parasitic | 1 | 2016 | 9 | 0.480 |
Why?
| | Lymphocytosis | 1 | 2016 | 12 | 0.470 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2016 | 24 | 0.470 |
Why?
| | Parotid Neoplasms | 1 | 2016 | 14 | 0.470 |
Why?
| | Enterobacteriaceae | 2 | 2013 | 44 | 0.470 |
Why?
| | Databases, Factual | 4 | 2025 | 1493 | 0.470 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2016 | 20 | 0.470 |
Why?
| | Diphyllobothriasis | 1 | 2015 | 2 | 0.460 |
Why?
| | Diphyllobothrium | 1 | 2015 | 2 | 0.460 |
Why?
| | Occupational Diseases | 1 | 2017 | 164 | 0.460 |
Why?
| | Colombia | 4 | 2020 | 41 | 0.460 |
Why?
| | Plasmablastic Lymphoma | 1 | 2015 | 8 | 0.460 |
Why?
| | Insect Vectors | 1 | 2015 | 39 | 0.450 |
Why?
| | Gamma Rays | 1 | 2015 | 56 | 0.450 |
Why?
| | Young Adult | 13 | 2026 | 14330 | 0.450 |
Why?
| | Transplants | 1 | 2015 | 36 | 0.450 |
Why?
| | Teicoplanin | 3 | 2026 | 15 | 0.440 |
Why?
| | Plasma Cells | 1 | 2015 | 80 | 0.440 |
Why?
| | Prognosis | 5 | 2026 | 4351 | 0.430 |
Why?
| | Animals | 18 | 2026 | 38107 | 0.430 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2018 | 272 | 0.420 |
Why?
| | Anemia | 1 | 2016 | 190 | 0.420 |
Why?
| | Glycopeptides | 2 | 2026 | 48 | 0.420 |
Why?
| | Heart Ventricles | 1 | 2019 | 762 | 0.420 |
Why?
| | Bone Marrow | 1 | 2016 | 310 | 0.410 |
Why?
| | Propensity Score | 3 | 2026 | 376 | 0.410 |
Why?
| | Treatment Outcome | 13 | 2026 | 11821 | 0.410 |
Why?
| | Thrombocytopenia | 1 | 2016 | 206 | 0.410 |
Why?
| | Lymphoma | 1 | 2016 | 251 | 0.410 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2023 | 441 | 0.400 |
Why?
| | Leprosy | 2 | 2026 | 25 | 0.400 |
Why?
| | Anaphylaxis | 2 | 2025 | 105 | 0.400 |
Why?
| | Postoperative Complications | 1 | 2026 | 3034 | 0.390 |
Why?
| | Environmental Exposure | 1 | 2018 | 578 | 0.390 |
Why?
| | Myocardial Contraction | 1 | 2015 | 292 | 0.390 |
Why?
| | Research | 1 | 2016 | 421 | 0.380 |
Why?
| | Thrombocytosis | 1 | 2013 | 6 | 0.380 |
Why?
| | Lymphoma, Primary Effusion | 1 | 2013 | 4 | 0.380 |
Why?
| | Betacoronavirus | 6 | 2020 | 288 | 0.380 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2013 | 13 | 0.380 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2026 | 72 | 0.370 |
Why?
| | Amphotericin B | 2 | 2025 | 36 | 0.370 |
Why?
| | Sepsis | 3 | 2026 | 669 | 0.370 |
Why?
| | Herpesvirus 8, Human | 1 | 2013 | 67 | 0.370 |
Why?
| | Antigens, Protozoan | 1 | 2012 | 32 | 0.360 |
Why?
| | Acinetobacter Infections | 1 | 2012 | 15 | 0.360 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2023 | 253 | 0.360 |
Why?
| | Proctitis | 1 | 2012 | 6 | 0.360 |
Why?
| | Acinetobacter | 1 | 2012 | 16 | 0.360 |
Why?
| | H-2 Antigens | 1 | 2012 | 111 | 0.360 |
Why?
| | Herpes Genitalis | 1 | 2012 | 17 | 0.360 |
Why?
| | Herpesvirus 2, Human | 1 | 2012 | 27 | 0.360 |
Why?
| | Cellulitis | 1 | 2012 | 55 | 0.350 |
Why?
| | Isoxazoles | 1 | 2012 | 57 | 0.350 |
Why?
| | Yellow Fever Vaccine | 2 | 2022 | 7 | 0.350 |
Why?
| | Severe Dengue | 1 | 2011 | 9 | 0.340 |
Why?
| | Acyclovir | 1 | 2012 | 97 | 0.340 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 147 | 0.340 |
Why?
| | Emigration and Immigration | 2 | 2022 | 67 | 0.330 |
Why?
| | Poliovirus | 2 | 2022 | 73 | 0.320 |
Why?
| | Healthcare Disparities | 3 | 2024 | 733 | 0.320 |
Why?
| | B-Lymphocytes | 1 | 2016 | 887 | 0.320 |
Why?
| | Pancreatitis | 1 | 2011 | 146 | 0.310 |
Why?
| | Moraxella | 1 | 2009 | 4 | 0.300 |
Why?
| | Moraxellaceae Infections | 1 | 2009 | 3 | 0.300 |
Why?
| | Repressor Proteins | 1 | 2013 | 430 | 0.300 |
Why?
| | Acute Lung Injury | 1 | 2013 | 312 | 0.300 |
Why?
| | Lung Diseases | 2 | 2018 | 787 | 0.290 |
Why?
| | Comorbidity | 4 | 2026 | 1665 | 0.290 |
Why?
| | Global Health | 4 | 2026 | 403 | 0.290 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3926 | 0.290 |
Why?
| | Lupus Nephritis | 1 | 2009 | 67 | 0.290 |
Why?
| | Aged, 80 and over | 6 | 2025 | 8391 | 0.290 |
Why?
| | Antibodies, Viral | 2 | 2025 | 689 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2623 | 0.290 |
Why?
| | Pulmonary Emphysema | 1 | 2011 | 276 | 0.280 |
Why?
| | Arthritis, Infectious | 1 | 2009 | 77 | 0.280 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1339 | 0.270 |
Why?
| | Fatal Outcome | 2 | 2019 | 302 | 0.270 |
Why?
| | Presenilin-1 | 1 | 2008 | 34 | 0.270 |
Why?
| | Seroepidemiologic Studies | 2 | 2025 | 171 | 0.270 |
Why?
| | Immunoglobulin G | 3 | 2023 | 901 | 0.270 |
Why?
| | Staphylococcal Infections | 3 | 2023 | 397 | 0.270 |
Why?
| | Engineering | 1 | 2018 | 31 | 0.270 |
Why?
| | Social Responsibility | 1 | 2018 | 52 | 0.260 |
Why?
| | Mycobacterium | 2 | 2018 | 102 | 0.250 |
Why?
| | Acute Kidney Injury | 2 | 2026 | 866 | 0.250 |
Why?
| | Echinocandins | 2 | 2023 | 8 | 0.250 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2018 | 122 | 0.240 |
Why?
| | Echinococcus | 1 | 2026 | 1 | 0.240 |
Why?
| | Vaccination | 3 | 2025 | 1449 | 0.240 |
Why?
| | Babesiosis | 1 | 2026 | 4 | 0.240 |
Why?
| | Public Health | 3 | 2020 | 574 | 0.240 |
Why?
| | Attitude | 1 | 2018 | 253 | 0.230 |
Why?
| | Coccidioides | 1 | 2025 | 7 | 0.230 |
Why?
| | Antiviral Agents | 1 | 2012 | 779 | 0.230 |
Why?
| | HIV | 2 | 2018 | 249 | 0.230 |
Why?
| | Tick Bites | 1 | 2025 | 6 | 0.230 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1998 | 0.230 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2025 | 49 | 0.220 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 612 | 0.220 |
Why?
| | Erythema Nodosum | 1 | 2025 | 6 | 0.220 |
Why?
| | Electrocardiography | 2 | 2019 | 667 | 0.220 |
Why?
| | Paresthesia | 1 | 2025 | 14 | 0.220 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1064 | 0.220 |
Why?
| | Clarithromycin | 1 | 2025 | 24 | 0.220 |
Why?
| | Leprosy, Lepromatous | 1 | 2025 | 8 | 0.220 |
Why?
| | Mental Disorders | 2 | 2025 | 1148 | 0.220 |
Why?
| | Erythromycin | 1 | 2025 | 19 | 0.220 |
Why?
| | Candida tropicalis | 1 | 2024 | 4 | 0.220 |
Why?
| | Shock, Septic | 2 | 2021 | 230 | 0.220 |
Why?
| | Gelatin | 1 | 2025 | 56 | 0.220 |
Why?
| | Uveitis, Anterior | 1 | 2025 | 27 | 0.220 |
Why?
| | Cross Reactions | 1 | 2025 | 130 | 0.220 |
Why?
| | Insect Bites and Stings | 1 | 2024 | 13 | 0.210 |
Why?
| | Prednisone | 1 | 2025 | 229 | 0.210 |
Why?
| | Strongyloides stercoralis | 1 | 2024 | 2 | 0.210 |
Why?
| | Azithromycin | 1 | 2025 | 101 | 0.210 |
Why?
| | Colorado | 3 | 2020 | 4595 | 0.200 |
Why?
| | Refugees | 1 | 2025 | 84 | 0.200 |
Why?
| | World Health Organization | 2 | 2021 | 104 | 0.200 |
Why?
| | Peru | 2 | 2024 | 61 | 0.200 |
Why?
| | Observational Studies as Topic | 2 | 2025 | 133 | 0.200 |
Why?
| | Meningoencephalitis | 1 | 2023 | 24 | 0.200 |
Why?
| | Toxoplasmosis | 1 | 2023 | 44 | 0.200 |
Why?
| | Toxoplasma | 1 | 2023 | 50 | 0.200 |
Why?
| | Voriconazole | 1 | 2023 | 21 | 0.200 |
Why?
| | Vancomycin | 4 | 2026 | 96 | 0.190 |
Why?
| | Alanine | 1 | 2024 | 171 | 0.190 |
Why?
| | Rabies Vaccines | 1 | 2022 | 4 | 0.190 |
Why?
| | Georgia | 2 | 2025 | 79 | 0.190 |
Why?
| | Rabies | 1 | 2022 | 5 | 0.190 |
Why?
| | Antiparasitic Agents | 1 | 2022 | 4 | 0.190 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 2113 | 0.190 |
Why?
| | Cohort Studies | 4 | 2026 | 6077 | 0.180 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1036 | 0.180 |
Why?
| | Pyridones | 1 | 2024 | 210 | 0.180 |
Why?
| | Americas | 1 | 2022 | 27 | 0.180 |
Why?
| | Students | 1 | 2018 | 649 | 0.180 |
Why?
| | Drug Monitoring | 1 | 2026 | 399 | 0.180 |
Why?
| | Kaplan-Meier Estimate | 1 | 2024 | 970 | 0.180 |
Why?
| | Disease Notification | 1 | 2022 | 16 | 0.180 |
Why?
| | Tenofovir | 1 | 2024 | 300 | 0.180 |
Why?
| | Travel Medicine | 2 | 2020 | 5 | 0.180 |
Why?
| | Sexually Transmitted Diseases | 1 | 2024 | 163 | 0.180 |
Why?
| | Italy | 1 | 2022 | 118 | 0.180 |
Why?
| | Pregnancy | 4 | 2024 | 7230 | 0.170 |
Why?
| | Tomography, X-Ray Computed | 4 | 2019 | 2786 | 0.170 |
Why?
| | Staphylococcal Skin Infections | 2 | 2012 | 40 | 0.170 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2023 | 238 | 0.170 |
Why?
| | Alzheimer Disease | 1 | 2008 | 641 | 0.170 |
Why?
| | Precision Medicine | 1 | 2026 | 462 | 0.170 |
Why?
| | Population Dynamics | 1 | 2022 | 142 | 0.170 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1331 | 0.170 |
Why?
| | Dog Diseases | 1 | 2022 | 140 | 0.160 |
Why?
| | Leishmania guyanensis | 1 | 2020 | 1 | 0.160 |
Why?
| | Phosphorylcholine | 1 | 2020 | 19 | 0.160 |
Why?
| | Antiprotozoal Agents | 1 | 2020 | 15 | 0.160 |
Why?
| | Personal Protective Equipment | 1 | 2021 | 59 | 0.160 |
Why?
| | Child | 8 | 2026 | 22693 | 0.160 |
Why?
| | Pericarditis | 1 | 2020 | 12 | 0.160 |
Why?
| | Leishmaniasis, Cutaneous | 1 | 2020 | 14 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2022 | 1224 | 0.160 |
Why?
| | Case-Control Studies | 3 | 2018 | 3647 | 0.160 |
Why?
| | Anti-Inflammatory Agents | 1 | 2024 | 474 | 0.160 |
Why?
| | Weight Gain | 1 | 2024 | 562 | 0.160 |
Why?
| | Vaccines | 1 | 2025 | 389 | 0.160 |
Why?
| | Rural Population | 2 | 2022 | 677 | 0.160 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 49 | 0.160 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 39 | 0.150 |
Why?
| | Africa | 1 | 2020 | 119 | 0.150 |
Why?
| | Late Onset Disorders | 1 | 2019 | 2 | 0.150 |
Why?
| | Immunization, Secondary | 1 | 2020 | 94 | 0.150 |
Why?
| | Bolivia | 1 | 2019 | 64 | 0.150 |
Why?
| | Developing Countries | 1 | 2022 | 312 | 0.150 |
Why?
| | Proteinuria | 1 | 2020 | 103 | 0.150 |
Why?
| | Infection Control | 1 | 2021 | 174 | 0.140 |
Why?
| | Invasive Fungal Infections | 1 | 2019 | 12 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2488 | 0.140 |
Why?
| | Cryptococcus gattii | 1 | 2018 | 1 | 0.140 |
Why?
| | Medical Errors | 1 | 2020 | 124 | 0.140 |
Why?
| | Dermatitis | 1 | 2018 | 20 | 0.140 |
Why?
| | Acute Disease | 2 | 2012 | 1038 | 0.140 |
Why?
| | Speech Disorders | 1 | 2018 | 29 | 0.140 |
Why?
| | Vulnerable Populations | 1 | 2020 | 178 | 0.140 |
Why?
| | Echocardiography | 2 | 2020 | 645 | 0.140 |
Why?
| | Prospective Studies | 4 | 2023 | 8123 | 0.140 |
Why?
| | Africa, Western | 1 | 2018 | 21 | 0.140 |
Why?
| | Computed Tomography Angiography | 1 | 2019 | 151 | 0.140 |
Why?
| | Stroke Volume | 1 | 2021 | 652 | 0.140 |
Why?
| | Raw Foods | 1 | 2018 | 3 | 0.140 |
Why?
| | Administration, Intravenous | 1 | 2019 | 172 | 0.140 |
Why?
| | Sexual and Gender Minorities | 1 | 2022 | 269 | 0.130 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 541 | 0.130 |
Why?
| | Sex Factors | 1 | 2024 | 2107 | 0.130 |
Why?
| | Itraconazole | 1 | 2017 | 8 | 0.130 |
Why?
| | Adolescent | 7 | 2026 | 22557 | 0.130 |
Why?
| | California | 1 | 2019 | 475 | 0.130 |
Why?
| | Prisoners | 1 | 2020 | 146 | 0.130 |
Why?
| | Food Microbiology | 1 | 2018 | 39 | 0.130 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 348 | 0.130 |
Why?
| | Emigrants and Immigrants | 1 | 2020 | 160 | 0.130 |
Why?
| | Time Factors | 2 | 2019 | 7109 | 0.130 |
Why?
| | Hyponatremia | 1 | 2018 | 42 | 0.130 |
Why?
| | Administration, Oral | 2 | 2020 | 872 | 0.130 |
Why?
| | Arrhythmias, Cardiac | 1 | 2020 | 358 | 0.130 |
Why?
| | Cytokines | 2 | 2022 | 2081 | 0.130 |
Why?
| | Disability Evaluation | 1 | 2019 | 297 | 0.130 |
Why?
| | Respiration, Artificial | 1 | 2022 | 711 | 0.130 |
Why?
| | Neoplasms | 1 | 2013 | 2954 | 0.120 |
Why?
| | Longitudinal Studies | 2 | 2019 | 3017 | 0.120 |
Why?
| | Follow-Up Studies | 1 | 2026 | 5439 | 0.120 |
Why?
| | Farmers | 1 | 2017 | 71 | 0.120 |
Why?
| | Research Design | 2 | 2021 | 1143 | 0.120 |
Why?
| | Arachis | 1 | 2017 | 108 | 0.120 |
Why?
| | Mebendazole | 1 | 2016 | 2 | 0.120 |
Why?
| | Strongyloides | 1 | 2016 | 2 | 0.120 |
Why?
| | Trichuris | 1 | 2016 | 3 | 0.120 |
Why?
| | Albendazole | 1 | 2016 | 5 | 0.120 |
Why?
| | Patient Safety | 1 | 2020 | 352 | 0.120 |
Why?
| | Ivermectin | 1 | 2016 | 15 | 0.120 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 266 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 731 | 0.120 |
Why?
| | Hematocrit | 1 | 2016 | 108 | 0.120 |
Why?
| | Socioeconomic Factors | 2 | 2020 | 1327 | 0.120 |
Why?
| | Hospitals, University | 1 | 2016 | 178 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2020 | 784 | 0.120 |
Why?
| | Praziquantel | 1 | 2015 | 7 | 0.120 |
Why?
| | Pharmacists | 1 | 2019 | 260 | 0.110 |
Why?
| | Anthelmintics | 1 | 2015 | 13 | 0.110 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 881 | 0.110 |
Why?
| | Clone Cells | 1 | 2016 | 259 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1503 | 0.110 |
Why?
| | Brain | 1 | 2008 | 2991 | 0.110 |
Why?
| | Hearing Loss | 1 | 2018 | 177 | 0.110 |
Why?
| | Genotype | 2 | 2012 | 1879 | 0.110 |
Why?
| | Disease Outbreaks | 3 | 2023 | 422 | 0.110 |
Why?
| | Recurrence | 1 | 2018 | 1133 | 0.110 |
Why?
| | Health Care Costs | 1 | 2018 | 423 | 0.110 |
Why?
| | Herpesvirus 4, Human | 1 | 2015 | 172 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 486 | 0.110 |
Why?
| | Migraine Disorders | 1 | 2016 | 109 | 0.100 |
Why?
| | Academic Medical Centers | 1 | 2018 | 561 | 0.100 |
Why?
| | Frontal Lobe | 1 | 2015 | 159 | 0.100 |
Why?
| | Biopsy | 2 | 2020 | 1075 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 157 | 0.100 |
Why?
| | Mycobacterium leprae | 2 | 2026 | 9 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1543 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5899 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2021 | 947 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2020 | 682 | 0.100 |
Why?
| | Hemoglobins | 1 | 2016 | 384 | 0.100 |
Why?
| | Lipids | 1 | 2019 | 714 | 0.100 |
Why?
| | Microbial Sensitivity Tests | 2 | 2026 | 367 | 0.100 |
Why?
| | Parasite Load | 1 | 2013 | 10 | 0.100 |
Why?
| | Intestines | 1 | 2016 | 351 | 0.090 |
Why?
| | Mycoplasma hominis | 1 | 2012 | 4 | 0.090 |
Why?
| | APACHE | 1 | 2013 | 67 | 0.090 |
Why?
| | Mycoplasma Infections | 1 | 2012 | 17 | 0.090 |
Why?
| | Klebsiella Infections | 1 | 2013 | 26 | 0.090 |
Why?
| | Health Status Disparities | 3 | 2020 | 322 | 0.090 |
Why?
| | Platelet Count | 1 | 2013 | 95 | 0.090 |
Why?
| | Clindamycin | 1 | 2012 | 14 | 0.090 |
Why?
| | Molecular Typing | 1 | 2012 | 21 | 0.090 |
Why?
| | Syncope | 1 | 2013 | 48 | 0.090 |
Why?
| | Intensive Care Units | 3 | 2025 | 925 | 0.090 |
Why?
| | Logistic Models | 1 | 2018 | 2126 | 0.090 |
Why?
| | Serratia Infections | 1 | 2012 | 8 | 0.090 |
Why?
| | Disease Progression | 2 | 2012 | 2867 | 0.090 |
Why?
| | Linkage Disequilibrium | 1 | 2013 | 260 | 0.090 |
Why?
| | Serratia marcescens | 1 | 2012 | 17 | 0.090 |
Why?
| | Feces | 1 | 2015 | 496 | 0.090 |
Why?
| | Central America | 2 | 2023 | 28 | 0.090 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 1244 | 0.090 |
Why?
| | Disease Eradication | 2 | 2022 | 9 | 0.090 |
Why?
| | Hedgehog Proteins | 1 | 2013 | 194 | 0.090 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2013 | 124 | 0.090 |
Why?
| | Thoracic Vertebrae | 1 | 2012 | 90 | 0.090 |
Why?
| | Blister | 1 | 2011 | 38 | 0.090 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2011 | 43 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2015 | 530 | 0.080 |
Why?
| | Spinal Fractures | 1 | 2012 | 81 | 0.080 |
Why?
| | Anti-HIV Agents | 2 | 2024 | 914 | 0.080 |
Why?
| | Microscopy | 1 | 2013 | 147 | 0.080 |
Why?
| | Poliovirus Vaccine, Oral | 2 | 2022 | 25 | 0.080 |
Why?
| | Viral Load | 2 | 2024 | 526 | 0.080 |
Why?
| | Soft Tissue Infections | 1 | 2011 | 42 | 0.080 |
Why?
| | Venezuela | 2 | 2021 | 7 | 0.080 |
Why?
| | Drug Resistance, Viral | 1 | 2012 | 127 | 0.080 |
Why?
| | Drug Resistance, Bacterial | 1 | 2012 | 185 | 0.080 |
Why?
| | HIV Seropositivity | 1 | 2011 | 118 | 0.080 |
Why?
| | Myocardium | 1 | 2016 | 948 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2026 | 1031 | 0.080 |
Why?
| | Prevalence | 1 | 2018 | 2861 | 0.080 |
Why?
| | Coinfection | 1 | 2012 | 143 | 0.080 |
Why?
| | Gene Expression | 1 | 2015 | 1463 | 0.080 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2013 | 241 | 0.080 |
Why?
| | Cross Infection | 1 | 2013 | 258 | 0.080 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 179 | 0.080 |
Why?
| | Penicillanic Acid | 1 | 2009 | 4 | 0.080 |
Why?
| | Piperacillin | 1 | 2009 | 7 | 0.080 |
Why?
| | Urinary Tract Infections | 1 | 2012 | 209 | 0.080 |
Why?
| | Bacterial Typing Techniques | 1 | 2009 | 40 | 0.080 |
Why?
| | Debridement | 1 | 2009 | 86 | 0.070 |
Why?
| | Mice | 3 | 2023 | 18297 | 0.070 |
Why?
| | Surgical Wound Infection | 1 | 2012 | 349 | 0.070 |
Why?
| | Hypertension | 1 | 2018 | 1272 | 0.070 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 234 | 0.070 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 432 | 0.070 |
Why?
| | Spinal Cord Injuries | 1 | 2012 | 238 | 0.070 |
Why?
| | Genes, Dominant | 1 | 2008 | 95 | 0.070 |
Why?
| | Socialization | 1 | 2018 | 23 | 0.070 |
Why?
| | Chromosome Disorders | 1 | 2008 | 46 | 0.070 |
Why?
| | Mortality | 2 | 2021 | 375 | 0.070 |
Why?
| | Needs Assessment | 2 | 2021 | 404 | 0.070 |
Why?
| | Point Mutation | 1 | 2008 | 232 | 0.060 |
Why?
| | Genetic Markers | 1 | 2008 | 340 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 297 | 0.060 |
Why?
| | DNA Mutational Analysis | 1 | 2008 | 410 | 0.060 |
Why?
| | Pedigree | 1 | 2008 | 512 | 0.060 |
Why?
| | Gene Frequency | 1 | 2008 | 496 | 0.060 |
Why?
| | Drug Resistance, Fungal | 1 | 2026 | 8 | 0.060 |
Why?
| | Pichia | 1 | 2026 | 20 | 0.060 |
Why?
| | Candida albicans | 1 | 2026 | 62 | 0.060 |
Why?
| | Leprostatic Agents | 1 | 2026 | 6 | 0.060 |
Why?
| | Chronic Disease | 1 | 2012 | 1827 | 0.060 |
Why?
| | Anemia, Hemolytic | 1 | 2026 | 21 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2599 | 0.060 |
Why?
| | New York City | 1 | 2025 | 89 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 589 | 0.060 |
Why?
| | Amyloid beta-Peptides | 1 | 2008 | 251 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2240 | 0.060 |
Why?
| | Genetic Testing | 1 | 2008 | 492 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2012 | 927 | 0.050 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 972 | 0.050 |
Why?
| | Antivenins | 1 | 2024 | 29 | 0.050 |
Why?
| | Moths | 1 | 2024 | 45 | 0.050 |
Why?
| | Aminobutyrates | 1 | 2024 | 31 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2012 | 959 | 0.050 |
Why?
| | Peptide Fragments | 1 | 2008 | 693 | 0.050 |
Why?
| | Ribonucleosides | 1 | 2023 | 8 | 0.050 |
Why?
| | Drug Substitution | 1 | 2024 | 62 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2018 | 930 | 0.050 |
Why?
| | Acetazolamide | 1 | 2023 | 26 | 0.050 |
Why?
| | Antibodies, Protozoan | 1 | 2023 | 41 | 0.050 |
Why?
| | Registries | 1 | 2013 | 2400 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 6034 | 0.050 |
Why?
| | Tetrazoles | 1 | 2023 | 50 | 0.050 |
Why?
| | Human Rights | 1 | 2023 | 19 | 0.050 |
Why?
| | Biphenyl Compounds | 1 | 2023 | 67 | 0.050 |
Why?
| | HIV Integrase Inhibitors | 1 | 2024 | 80 | 0.050 |
Why?
| | Panama | 1 | 2022 | 11 | 0.050 |
Why?
| | Medicine, Traditional | 1 | 2022 | 22 | 0.050 |
Why?
| | Yellow fever virus | 1 | 2022 | 4 | 0.050 |
Why?
| | Monkeypox virus | 1 | 2022 | 23 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 190 | 0.050 |
Why?
| | Standard of Care | 1 | 2023 | 81 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2814 | 0.050 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 2022 | 27 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2023 | 284 | 0.050 |
Why?
| | CD4 Lymphocyte Count | 1 | 2023 | 280 | 0.050 |
Why?
| | Benzimidazoles | 1 | 2023 | 191 | 0.050 |
Why?
| | Sex Offenses | 1 | 2025 | 199 | 0.040 |
Why?
| | Mexico | 1 | 2022 | 233 | 0.040 |
Why?
| | Cameroon | 1 | 2021 | 8 | 0.040 |
Why?
| | Cuba | 1 | 2021 | 15 | 0.040 |
Why?
| | Violence | 1 | 2025 | 275 | 0.040 |
Why?
| | Contact Tracing | 1 | 2021 | 26 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2022 | 218 | 0.040 |
Why?
| | Adenine | 1 | 2024 | 339 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4580 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2219 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 6073 | 0.040 |
Why?
| | Dogs | 1 | 2022 | 517 | 0.040 |
Why?
| | Minority Health | 1 | 2021 | 18 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2022 | 231 | 0.040 |
Why?
| | Curriculum | 1 | 2018 | 1079 | 0.040 |
Why?
| | Cardiovascular Infections | 1 | 2020 | 1 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2025 | 1051 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 10 | 0.040 |
Why?
| | History, 17th Century | 1 | 2020 | 14 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 173 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 286 | 0.040 |
Why?
| | Bone Diseases, Infectious | 1 | 2020 | 8 | 0.040 |
Why?
| | Social Justice | 1 | 2021 | 83 | 0.040 |
Why?
| | Crowding | 1 | 2020 | 37 | 0.040 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2024 | 438 | 0.040 |
Why?
| | Policy Making | 1 | 2020 | 83 | 0.040 |
Why?
| | Inflammation | 2 | 2022 | 2919 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2020 | 88 | 0.040 |
Why?
| | Brazil | 1 | 2020 | 179 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 440 | 0.040 |
Why?
| | History, 21st Century | 1 | 2020 | 224 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 5246 | 0.040 |
Why?
| | Catheter-Related Infections | 1 | 2020 | 101 | 0.040 |
Why?
| | Frail Elderly | 1 | 2020 | 141 | 0.040 |
Why?
| | Hemorrhage | 1 | 2024 | 825 | 0.040 |
Why?
| | Cough | 1 | 2020 | 123 | 0.040 |
Why?
| | History, 20th Century | 1 | 2020 | 330 | 0.040 |
Why?
| | Southeastern United States | 1 | 2018 | 37 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2023 | 459 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 349 | 0.030 |
Why?
| | Immunization Schedule | 1 | 2020 | 187 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2020 | 152 | 0.030 |
Why?
| | Drug Compounding | 1 | 2019 | 106 | 0.030 |
Why?
| | Nursing Homes | 1 | 2020 | 171 | 0.030 |
Why?
| | Immunologic Factors | 1 | 2020 | 244 | 0.030 |
Why?
| | HIV-1 | 1 | 2024 | 913 | 0.030 |
Why?
| | Risk | 1 | 2020 | 920 | 0.030 |
Why?
| | Social Determinants of Health | 1 | 2022 | 317 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2020 | 385 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 561 | 0.030 |
Why?
| | Urban Population | 1 | 2020 | 497 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 738 | 0.030 |
Why?
| | Critical Illness | 1 | 2023 | 908 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2020 | 356 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3930 | 0.030 |
Why?
| | Mass Screening | 1 | 2022 | 1307 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 992 | 0.030 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2012 | 22 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2012 | 74 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3712 | 0.020 |
Why?
| | Infant | 1 | 2021 | 10114 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2022 | 0.020 |
Why?
| | Lung | 1 | 2020 | 4122 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 11913 | 0.010 |
Why?
|
|
Henao Martinez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|